US FDA Approved Zydus Lifesciences Cancer Drug in American Market

HEALTHCARE

Zydus Lifesciences said it has received approval from the US Food and Drug Administration (FDA) to sell Lenalidomide capsules, which are used for the treatment of different types of cancers, in the US market.

Zydus Lifesciences received approval from the US FDA to market the product or drug in strengths of 2.5, 5, 10, 15, 20, and 25 mg. Lenalidomide tablets are used to treat different types of cancer. The tablets work by stopping or decreasing the growth of cancer cells. The medicine is also used to treat anemia in patients with several blood and bone marrow disorders.

According to Zydus Lifesciences, the drug will be manufactured at the formulation facility of the company at Ahmedabad SEZ. Sharvil Patel, managing director of Zydus Lifesciences, said that the company remains focused on providing patients access to affordable medication, and US FDA approval of Lenalidomide Capsules is yet another step in the endeavour. Zydus Lifesciences said the product will be launched in the American market soon.

See also  Cadilla Healthcare Changed Name to Zydus Lifesciences Limited

According to data from IQVIA MAT, Lenalidomide tablets had annual sales of 2.86 billion dollars in the United States.